Telix Pharmaceuticals

Telix Pharmaceuticals, based in Melbourne and listed as TLX.AX, is the Australian theranostics company behind the Illuccix and Gozellix kits for gallium-68 PSMA-11 imaging and a broad therapeutic pipeline. It completed its acquisition of RLS (USA) in January 2025; the FDA approved Pixclara, its brain cancer imaging agent, in September 2026; and on 21 September 2026 Telix agreed to acquire ITM Isotope Technologies Munich for 1.65 billion US dollars upfront, mostly in Telix shares, plus up to 700 million dollars tied to ITM-11 approvals and sales, subject to Telix shareholder and regulatory approval and expected to close by the end of 2026. TLX250-CDx, or zirconium-89 girentuximab for carbonic anhydrase IX PET in kidney cancer, received an FDA complete response letter in 2025, TLX591, or lutetium-177 rosopatamab, a PSMA antibody in the ProstACT phase 3, and TLX101 for glioma follow. OnCo links it to prostate cancer and renal cell carcinoma, to PSMA as a target, to CAIX PET and PET tracer manufacturing, and to the idea of CAIX theranostics pairing girentuximab imaging with lutetium or actinium therapy. Whether an antibody-based PSMA therapy can compete with small-molecule ligands is the open question. Illuccix has its own page.